Cargando…

Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome

INTRODUCTION: Twenty-four-hour urinary free cortisol (24h-UFC) is the most used test for follow-up decision-making in patients with Cushing syndrome (CS) under medical treatment. However, 24h-UFC determinations by immunoassays (IA) are commonly overestimated because of steroid metabolites’ cross-rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vega-Beyhart, Arturo, Laguna-Moreno, Javier, Díaz-Catalán, Daniela, Boswell, Laura, Mora, Mireia, Halperin, Irene, Casals, Gregori, Hanzu, Felicia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905543/ https://www.ncbi.nlm.nih.gov/pubmed/35282465 http://dx.doi.org/10.3389/fendo.2022.833644

Ejemplares similares

RF21 | PSAT99 Urinary adrenal steroidome modifications by Ketoconazole and Metyrapone alter the urinary free cortisol immunoassay reliability in Cushing Syndrome
por: Vega-Beyhart, Arturo, et al.
Publicado: (2022)

Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry?
por: Casals, Gregori, et al.
Publicado: (2020)

OR03-05 Novel Lipidome Signature in Active Cushing Syndrome Revealed by UHPLC-MS Metabolomics
por: Vega-Beyhart, Arturo, et al.
Publicado: (2020)

Metyrapone for Long-Term Medical Management of Cushing's Syndrome
por: Traina, Andrea N., et al.
Publicado: (2013)

Cushing Disease Treated Successfully With Metyrapone During Pregnancy
por: Bass, Ilana Ramer, et al.
Publicado: (2021)

Circulatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface Markers
por: Aranda, Gloria, et al.
Publicado: (2017)

Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing’s Syndromes Treatment: Case Presentations
por: Yoshida, Kenichi, et al.
Publicado: (2018)

Long-term Treatment With Metyrapone in a Man With Ectopic Cushing Syndrome
por: Wong, Tin Wai
Publicado: (2022)

Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report
por: Boswell, Laura, et al.
Publicado: (2021)

Adrenal Cushing’s in Pregnancy, Managed with Metyrapone to Optimize for Adrenalectomy at 27 Weeks Gestation
por: Shah, Leena, et al.
Publicado: (2021)

Tumor Shrinkage by Metyrapone in Cushing Disease Exhibiting Glucocorticoid-Induced Positive Feedback
por: Tsujimoto, Yasutaka, et al.
Publicado: (2021)

Adrenal Cushing Syndrome Diagnosed During Pregnancy: Successful Medical Management With Metyrapone
por: Azzola, Alescia, et al.
Publicado: (2020)

Comparison of Direct and Extraction Immunoassay Methods With Liquid Chromatography-Tandem Mass Spectrometry Measurement of Urinary Free Cortisol for the Diagnosis of Cushing’s Syndrome
por: Mu, Danni, et al.
Publicado: (2024)

High variability in baseline urinary free cortisol values in patients with Cushing’s disease
por: Petersenn, S, et al.
Publicado: (2014)

Metyrapone Treatment in Endogenous Cushing’s Syndrome: Results at Week 12 From PROMPT, a Prospective International Multicenter, Open-Label, Phase III/IV Study
por: Nieman, Lynnette K, et al.
Publicado: (2021)

Synergistic cortisol suppression by ketoconazole–osilodrostat combination therapy
por: Amodru, Vincent, et al.
Publicado: (2021)

Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study
por: Puglisi, Soraya, et al.
Publicado: (2018)

SUN-LB068 Ectopic Cushing Syndrome Due to a Metastatic Neuroendocrine Tumor Treated with Metyrapone
por: Tsomos, Effie, et al.
Publicado: (2019)

Evaluation of ketoconazole as a treatment for Cushing’s disease in a retrospective cohort
por: Viecceli, Camila, et al.
Publicado: (2022)

Diagnosis of Cushing's disease in a patient with consistently normal urinary free cortisol levels: a case report
por: Moloney, Kelley J., et al.
Publicado: (2016)

Metyrapone: Various toxicities: case report
Publicado: (2021)

MON-172 Comparison of a Late-night Salivary Cortisol Immunoassay and a Cortisol and Cortisone LCMS Assay in Patients with Cushing’s Disease
por: Kannankeril, Joshua, et al.
Publicado: (2020)

Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing’s Syndrome: Results From a Single Center Cohort Study
por: Detomas, Mario, et al.
Publicado: (2022)

On-Chip Immunoassay for Determination of Urinary Albumin
por: Laiwattanapaisal, Wanida, et al.
Publicado: (2009)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

Ketoconazole as second-line treatment for Cushing’s disease after transsphenoidal surgery: systematic review and meta-analysis
por: Viecceli, Camila, et al.
Publicado: (2023)

Ketoconazole Allergy
por: Ensina, Luis Felipe, et al.
Publicado: (2009)

Urinary cortisol‐creatinine ratio in dogs with hypoadrenocorticism
por: Del Baldo, Francesca, et al.
Publicado: (2022)

Fluconazole as a Safe and Effective Alternative to Ketoconazole in Controlling Hypercortisolism of Recurrent Cushing’s Disease: A Case Report
por: Teng Chai, Shu, et al.
Publicado: (2018)

LBSAT59 Overnight Metyrapone Test And Urine Steroid Profiling In Patients Treated With Chronic Opioid Therapy: Prevalence Of Adrenal Insufficiency
por: Saini, Jasmine, et al.
Publicado: (2022)

Maternal Metyrapone Use During Breastfeeding: Safe for the Breastfed Infant
por: Duke, Madeline E, et al.
Publicado: (2019)

Erratum for “Urinary cortisol‐creatinine ratio in dogs with hypoadrenocorticism”
Publicado: (2023)

Urinary Steroid Profile in Ironman Triathletes
por: Marcos-Serrano, Marta, et al.
Publicado: (2018)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

FRI266 Medical Management Of Cushing’s Syndrome Caused By Primary Bilateral Macronodular Adrenal Hyperplasia (PBMA) With Low Dose Of Ketoconazole
por: Hatfield, Jennifer S, et al.
Publicado: (2023)

SAT302 Circulating And Urinary Metabolites Associated With Total Exposure Of Cortisol And Cortisol Time Profile
por: McQueen, Johanna, et al.
Publicado: (2023)

Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion.
por: Fredrikson, M., et al.
Publicado: (1992)

Is there an association between fibromyalgia and below-normal levels of urinary cortisol?
por: Izquierdo–Álvarez, Silvia, et al.
Publicado: (2008)

Urinary cortisol and depression in early pregnancy: role of adiposity and race
por: Luiza, John W, et al.
Publicado: (2015)

Higher urinary cortisol levels associate with increased cardiovascular risk
por: Haas, Andrea V, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e387hno3sp4eg1ad177h2tqagd